ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
26 announcements with these filters
Bajaj Healthcare delivered strong H1 growth led by a 82% surge in formulations and key new specialty launches.
Bajaj Healthcare reported Q2 FY27 revenue of ₹175.9 Crore, up 18.9% YoY. EBITDA stood at ₹32.1 Crore, reflecting a 12.2% YoY increase.
Bajaj Healthcare filed its Monitoring Agency Report for the quarter ended September 30, 2026, as required by SEBI regulations for the utilization of preferential issue proceeds.
Bajaj Healthcare Ltd reported revenue from operations of ₹175.9 Cr (+18.9% YoY) and net profit of ₹14.1 Cr (+27.0% YoY) for Q2 FY27.
Bajaj Healthcare received NCLT approval to acquire Genrx Pharmaceuticals Private Limited as a going concern. The entity will become a wholly owned subsidiary.
Bajaj Healthcare Limited has executed a deed of assignment to sell its undertaking located in Dahej Industrial Area, Gujarat, for approximately Rs. 14.67 Crore.
Bajaj Healthcare Limited announced a board meeting on October 17, 2026, to approve the company's un-audited financial results for the quarter and half-year ended September 30, 2026.
Bajaj Healthcare Limited concluded its 33rd Annual General Meeting on September 21, 2026. The shareholders transacted ordinary and special business, including a final dividend declaration.
Bajaj Healthcare Limited has fixed September 14, 2026, as the record date for a 30% final dividend. The dividend of ₹1.50 per share awaits shareholder approval.
Bajaj Healthcare dispatched letters to shareholders providing the web-link for the 2025-26 Annual Report and reminding them to update their KYC details.
Bajaj Healthcare Limited submitted its Business Responsibility and Sustainability Report for the financial year 2025-26, detailing the company's operational and sustainability performance.
Bajaj Healthcare Limited has scheduled its 33rd Annual General Meeting for September 21, 2026. The Annual Report for FY 2025-26 has been dispatched to shareholders.
Bajaj Healthcare has allotted 2,500 equity shares upon the exercise of employee stock options under its 2024 scheme, slightly increasing the company's total issued equity capital.
Bajaj Healthcare received DCGI approval to manufacture and market Cenobamate API and tablets across six strengths in India. This adds a new product to its portfolio.
India Ratings upgraded Bajaj Healthcare's long-term and short-term bank loan facilities to 'IND A' and 'IND A1'. The upgrade reflects improved business and financial profiles.
Q1FY27 revenue grew 11.3% YoY to INR 165.6 Cr with PAT at INR 13.9 Cr. Focus shifting toward high-margin peptides, oncology APIs, and specialized formulations.
Bajaj Healthcare is pivoting from high-volume commodities to high-margin specialized APIs and formulations, targeting a ₹1000 Cr topline via new oncology and peptide capacities.
Bajaj Healthcare announced the continuation of Mr. Gopalakrishnan Kesavan as Non-Executive Independent Director. He remains on the board after attaining 75 years of age.
Bajaj Healthcare Limited granted 275 stock options to eligible employees under its 2024 ESOP plan at an exercise price of ₹5 per share.
Bajaj Healthcare's Q1 FY27 revenue rose 11.3% YoY to Rs. 165.6 Crore, with PAT growing 15.8% to Rs. 13.7 Crore. Operational updates included new product commercialization milestones.
Bajaj Healthcare Ltd filed its monitoring agency report for the quarter ended June 30, 2026, confirming nil deviation in the utilization of preferential issue proceeds.
Bajaj Healthcare Ltd reported revenue from operations of ₹165.6 Cr (+11.3% YoY) and net profit of ₹13.7 Cr (+16.1% YoY) for Q1 FY27.
Bajaj Healthcare scheduled a board meeting on July 20, 2026. The board will consider un-audited financial results for the June quarter.
Bajaj Healthcare received SEC-CDSCO recommendation to manufacture and market Cenobamate Tablets. This regulatory milestone supports the company's growth in the specialty pharmaceuticals segment.
Anil Champalal Jain, a promoter, acquired 1,00,000 shares of Bajaj Healthcare Ltd on an open market basis. This raises promoter stake, indicating confidence while no transaction value disclosed.
Bajaj Healthcare Limited submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report by a Practicing Company Secretary confirms overall compliance with SEBI regulations.